Adjuvant imatinib in GIST: 3 years and genotype

A 52-year-old man undergoes surgery for a 9-centimeter tumor on the stomach wall, discovered after an episode of gastrointestinal bleeding. The resection is complete, with no rupture reported. The pathology report confirms a gastrointestinal stromal tumor (GIST), with 12 mitoses per 5 square millimeters. The surgeon refers him to the oncologist with a simple question: imatinib for how long? The oncologist sends back another: did anyone order KIT and PDGFRA mutation analysis? The scene is fictional and was written for teaching.

This text uses the case as a clinical reasoning scenario for students and health professionals. The topic is adjuvant imatinib in resected GIST, based on the SSGXVIII/AIO trial, which compared 1 and 3 years of treatment. The question Dr. Alexei proposed for the series brings together two points: who should receive imatinib after surgery, and why does the genotype need to be on the table before deciding? The text does not replace your country's guideline or your institution's protocol. If you play the case of the day on NEXO, you will recognize the pattern: the same diagnosis can hide diseases that respond very differently to the same drug.

Key points

• Adjuvant imatinib is indicated for GIST with high risk of recurrence after complete resection.
• In SSGXVIII/AIO, 3 years of imatinib 400 mg daily reduced recurrence and death compared with 1 year.
• The greater benefit appeared in tumors with a deletion or indel in exon 11 of KIT.
• Tumors with PDGFRA D842V and GIST without a KIT or PDGFRA mutation do not respond to imatinib and should not receive it as adjuvant therapy.
• Mutations in exon 9 of KIT behave differently, and the ideal dose in the adjuvant setting remains under debate.
• Tumor rupture greatly changes the risk and must be defined with clear criteria.

Why this is a reasoning scenario

GIST is the most common sarcoma of the digestive tract and arises most often in the stomach. Surgery cures many patients with localized disease, but not all. The review by Iwatsuki and colleagues notes that complete resection is possible in up to 85 of every 100 patients with primary disease, and that about half develop recurrence or metastasis within 5 years (Iwatsuki and colleagues, 2019). That average hides an enormous variation: some tumors almost never come back, and others come back almost always.

Imatinib changed the history of advanced GIST, and was later taken into the adjuvant setting. But giving a drug for years to someone already cured by surgery exposes them to toxicity without benefit. And giving the drug to someone with a resistant tumor exposes them to toxicity with no chance of benefit. The clinical reasoning here is one of selection: who has a high enough risk, and who has a tumor that responds to imatinib?

The answer depends on two sets of information. The first is clinical and pathological: size, mitoses, location and rupture. The second is molecular: which mutation the tumor has. Both need to be ready before the first prescription. The post on when to seek a sarcoma center shows why this assessment works better in experienced teams.

It is also a rare disease. The same review estimates the incidence at 10 to 15 new diagnoses per million people per year (Iwatsuki and colleagues, 2019). Many general oncologists see few patients with GIST per year, which makes it easy to forget a step that is not part of the routine for other tumors, such as ordering sequencing before prescribing.

What makes this error easy to make

Many GIST pathology reports arrive with the diagnosis confirmed by immunohistochemistry, with KIT (CD117) or DOG1 positive, and without molecular analysis. KIT positivity on immunohistochemistry is often confused with the presence of a sensitive mutation, which is not the same thing. A tumor can stain strongly for KIT and have a PDGFRA mutation resistant to imatinib. Without sequencing, the adjuvant decision is made in the dark.

How to estimate the risk of recurrence

Risk classification has evolved over time. The 2023 guideline from the Spanish sarcoma group (GEIS) sums up this history: the first criteria used size and mitoses, those of Miettinen and Lasota added location, and the modified NIH criteria included rupture, serving as the basis for the randomized studies (Serrano et al., 2023). Gastric tumors have a better prognosis than small bowel tumors of the same size and with the same mitoses.

• Size: the larger the tumor, the higher the risk.
• Mitotic index: counted in 5 square millimeters or in 50 high-power fields, it is one of the strongest factors.
• Location: tumors outside the stomach carry a higher risk.
• Rupture: it greatly increases the risk of peritoneal recurrence.

Joensuu et al. used the SSGXVIII data to identify the factors linked to recurrence in patients treated with adjuvant imatinib. Five factors had an independent association with worse recurrence-free survival: high mitotic index, location outside the stomach, large size, rupture and treatment for only 12 months (Joensuu et al., 2014). A simple score, with mitoses and location, separated groups with 5-year recurrence-free survival of about 77, 48 and 8 per 100 patients.

The intermediate risk

The intermediate-risk group is the hardest. The British Sarcoma Group guideline cites a study of 2,560 patients in which, by the modified NIH criteria, intermediate-risk patients without rupture had a prognosis similar to that of low-risk patients and would not need adjuvant therapy, while high-risk patients had a clearly worse recurrence rate (Judson et al., 2025). Zhang and Liu note that other factors, such as gastrointestinal bleeding and a high Ki67 index, have also been linked to a worse prognosis, and that current classifications are still insufficient (Zhang and Liu, 2020).

What SSGXVIII tested

SSGXVIII/AIO was a Scandinavian and German multicenter study. It included 400 patients at high risk of GIST recurrence after macroscopically complete surgery, between 2004 and 2008, and randomized them to imatinib 400 mg a day for 1 year or for 3 years (Joensuu et al., 2023). High risk was defined by the modified NIH criteria, according to the GEIS guideline (Serrano et al., 2023).

The question was not whether imatinib worked, because the American ACOSOG Z9001 study had already shown a gain in recurrence-free survival with 1 year of treatment versus placebo. The question was whether treating for longer brought an additional gain. Joensuu notes that SSGXVIII is the only randomized study that showed a gain in overall survival with adjuvant imatinib and the only one that assessed a duration longer than 2 years (Joensuu, 2023).

The dose and how to take it

The dose studied was 400 mg by mouth, once a day (Joensuu et al., 2023). The tablet is usually taken with a meal and a glass of water, to reduce nausea. Check the package insert in your country and the interactions, because imatinib is metabolized by the CYP3A4 cytochrome.

What SSGXVIII showed

In the long-term analysis summarized by Joensuu, 10-year recurrence-free survival was about 53 per 100 patients in the 3-year group versus 42 in the 1-year group, and 10-year overall survival was 79 versus 65 per 100, with a hazard ratio of 0.55 (Joensuu, 2023). When patients without GIST on histological review and those who already had metastatic disease at entry were excluded, 10-year overall survival was about 82 versus 67 per 100.

The same author sums up the effect as a reduction of about 45 per 100 in the risk of death in the first 10 years, even with patients who, looking at it today, should not have been included, such as those with resistant mutations (Joensuu, 2023). This suggests that, with current molecular selection, the real gain in the right patients is even greater.

Genotype	Sensitivity to imatinib	What the data show	Usual adjuvant approach
KIT exon 11 (deletion or indel)	High	Greater gain with 3 years in SSGXVIII	Imatinib 400 mg a day for 3 years if high risk
KIT exon 11 (substitution or duplication)	High	Better prognosis; less clear benefit	Discuss according to risk
KIT exon 9	Intermediate	Poor survival regardless of duration in SSGXVIII	Imatinib if high risk; dose under debate
PDGFRA D842V	Resistant	No response to imatinib in advanced disease	Do not use adjuvant imatinib
PDGFRA non-D842V	Generally sensitive	Responses in advanced disease	Discuss according to risk
No KIT or PDGFRA mutation	Low or none	Includes SDH, NF1 and BRAF, not sensitive	Do not use adjuvant imatinib

Genotype changes the decision

The molecular analysis of SSGXVIII was done in 341 patients with confirmed localized GIST. With a median follow-up of 10 years, patients with deletion or indel in KIT exon 11 treated for 3 years lived longer than those treated for 1 year: 10-year overall survival of 86 versus 64 per 100, with a hazard ratio of 0.34 (Joensuu and colleagues, 2023). 10-year recurrence-free survival was also higher, 47 versus 29 per 100. Patients with exon 9 mutation, in turn, had unfavorable survival with either duration.

Joensuu concludes that there is little evidence of survival gain in randomized studies for tumors with exon 9 mutation, with insertion in KIT, with PDGFRA D842V or without KIT and PDGFRA mutation (Joensuu, 2023). Adjuvant imatinib improves survival substantially when the tumor is high risk, the treatment lasts long enough and the mutation is sensitive.

How often each mutation appears

Joensuu summarizes the distribution: KIT exon 11 mutations are the most common, in about 65 per 100 GIST, most of them deletions or indels, but also substitutions and insertions or duplications (Joensuu, 2023). Exon 9 mutations appear in 6 to 8 per 100 localized GIST and usually arise in the small intestine. Tumors with PDGFRA mutation usually arise in the stomach and generally have a favorable prognosis. Tumors with exon 9 tend to have a more aggressive course than those with exon 11.

This distribution explains why the patient in the scene, with a gastric tumor, may have either a deletion in exon 11, which calls for 3 years of imatinib, or a PDGFRA mutation, which may be D842V and not respond. The stomach concentrates both possibilities. Only sequencing separates one from the other, and it should be requested on the surgical specimen, or on the biopsy when treatment starts before surgery.

In practice, it is worth agreeing with pathology that every GIST with a possible indication for adjuvant treatment goes for routine molecular analysis. This avoids the situation in which the oncologist finds out, months later, that the patient took a drug with no effect on their tumor.

PDGFRA D842V

The D842V substitution in exon 18 is the most frequent alteration among GIST with PDGFRA mutation, present in 65 to 75 per 100 of these tumors, according to the GEIS guideline (Serrano and colleagues, 2023). In a Korean registry of advanced disease, Yoo and colleagues found an objective response in none of the patients with D842V treated with imatinib, versus 5 of 7 with other PDGFRA mutations, and median progression-free survival was 3.8 versus 29.5 months (Yoo and colleagues, 2016). Giving adjuvant imatinib to this patient means exposing them to toxicity with no expected benefit.

KIT exon 9

According to the GEIS guideline, exon 9 mutations appear in 12 to 15 per 100 GIST, are linked to small intestine location and to greater malignant potential (Serrano and colleagues, 2023). The dose of 800 mg per day is used by some services, by extension from advanced disease. Vincenzi and colleagues gathered 185 patients from 23 European reference centers and found no advantage of the 800 mg per day dose over 400 mg in any survival outcome (Vincenzi and colleagues, 2022). The factors linked to worse evolution were high mitotic index and location outside the stomach. The authors call for prospective studies.

GIST without KIT or PDGFRA mutation

These tumors form a heterogeneous group, more common in children and young women. Joensuu notes that none of the alterations found in this group, such as SDH mutations, SDHC promoter silencing, NF1 and BRAF, is sensitive to imatinib (Joensuu, 2023). Some progress very slowly. SDH-deficient GIST may be part of hereditary syndromes, such as Carney triad, which calls for family investigation.

Rupture: a factor that weighs heavily

Tumor rupture, before or during surgery, spreads cells through the peritoneum and greatly increases the risk of recurrence. The problem was that there was no common definition. Nishida and colleagues reviewed the literature and, based on the Oslo criteria, proposed six situations that count as rupture (Nishida and colleagues, 2019):

• tumor fracture or spillage of contents;
• bloody ascites;
• perforation of the digestive tract at the tumor site;
• microscopic infiltration of an adjacent organ;
• dissection within the lesion or removal in fragments;
• incisional biopsy.

The same authors list what should not count as rupture, such as mucosal defects, spillage contained within the organ lumen, uncomplicated needle biopsy and R1 resection. The distinction matters because it changes the recommended duration of treatment.

In SSGXVIII, about 20 in every 100 patients with confirmed localized GIST had a reported rupture. These patients had 10-year recurrence-free survival of 21 versus 55 in every 100 without rupture, and overall survival of 59 versus 78 (Joensuu and colleagues, 2024). The 3 years did not significantly improve outcomes for the rupture group as a whole, but in the subgroup with deletion or indel in exon 11, 10-year overall survival was 94 versus 54 in every 100 with 3 years versus 1 year. The authors note that about one fifth of the ruptured tumors treated did not recur.

How to talk about rupture with the patient

Rupture is often seen as a failure, and the patient may feel that something went wrong in surgery. It is worth explaining that it can happen before the operation, through bleeding or spontaneous perforation, and that treatment exists precisely to reduce the risk. Nishida and colleagues recall that guidelines indicate adjuvant treatment for a defined period or even for life in cases with rupture (Nishida and colleagues, 2019). Detailed recording of what happened in the operating room is what allows the rupture to be classified later.

Tolerance, adherence and duration

Three years of a daily tablet is a long commitment. A Danish quality assurance study by Mohammad and colleagues followed 65 patients on adjuvant treatment and found dose reduction due to adverse effects in 58 in every 100 and discontinuation in 17 in every 100 (Mohammad and colleagues, 2026). Recurrence occurred in 23 in every 100 patients, with a median of 4.5 years from diagnosis, with no significant difference between those who reduced or stopped and those who did not.

What the patient usually feels

In the Danish study, the most common adverse effects were fatigue and edema, and one third of the patients who needed a dose reduction had some grade 3 effect (Mohammad and colleagues, 2026). Most continued on 400 mg a day, and the second most used regimen was 300 mg a day. The authors also report that, in a study they cite with 6 years of treatment, abdominal pain, diarrhea, vomiting and asthenia appeared at close to double the frequency.

• Ask about fatigue and swelling at every visit.
• Adjust the dose before the patient abandons treatment.
• Record interruptions and restarts.
• Agree with the patient what to do when a new effect appears.

The key point is that the patient knows they can and should report symptoms, instead of stopping the medicine on their own. Dose reduction, when well managed, keeps the patient in treatment.

More than 3 years?

The British Sarcoma Group guideline recommends 3 years of adjuvant imatinib for patients at high risk of recurrence, provided the tumor is not likely to be resistant, above all excluding the D842V mutation in exon 18 of PDGFRA (Judson and colleagues, 2025). The same guideline states that this recommendation may change once the results of the SSG XXII study, which compared 3 with 5 years of adjuvant treatment, are known. Prolonging treatment is an individual decision, discussed with the patient.

Follow-up after imatinib

Relapse usually appears in the first years after imatinib is stopped, not during treatment. For this reason, follow-up with abdominal CT should be closer right after the end of the 3 years. The GEIS guideline notes that, even in localized GIST, metastatic relapse occurs in about 40 out of every 100 patients (Serrano et al., 2023).

Relapse can also be the first opportunity to review the genotype. If the mutation was not tested in the original specimen, it should be requested before any new treatment. The Spanish guideline currently lists five drugs approved for GIST: imatinib, sunitinib, regorafenib, ripretinib and avapritinib, the latter active against PDGFRA D842V (Serrano et al., 2023).

When imatinib comes before surgery

In large tumors or in difficult locations, imatinib can be given before surgery to reduce the size and allow a smaller operation. In this case, the genotype needs to be known even earlier, at biopsy. The post on neoadjuvant imatinib in GIST covers this scenario.

How NEXO helps train this reasoning

In NEXO, the case of the day is fictional, with a real clinical presentation and up to six progressive clues, and you propose the diagnosis by looking for the ICD-10 code. Adjuvant GIST is a good exercise because the same name on the report hides tumors with opposite behaviors, and the decisive clue is a test that must be remembered. The post on differential diagnosis shows how to organize the clues, and the post on clinical decision-making helps you think about the value of each test.

Three exercises with cases

Change the mutation. Say what changes if sequencing shows PDGFRA D842V instead of a deletion in exon 11 of KIT.

Change the location. Say how the risk changes if the same tumor were in the jejunum.

Change the surgery. Say what you would do if the operative description reported spillage of tumor contents.

The post on diagnostic uncertainty helps in the conversation about intermediate risk. The limits of use of the game are described on the NEXO economy page. If you research the teaching of clinical reasoning, the page for researchers explains how to get in touch. Professionals who write or review cases find information in curation and in creators, and institutions can learn about the proposal on the partnerships page.

Frequently asked questions

Who should receive adjuvant imatinib?

Patients with high-risk GIST after complete resection and with an imatinib-sensitive mutation (Joensuu, 2023).

What is the dose and for how long?

In SSGXVIII, 400 mg orally once a day, for 3 years (Joensuu et al., 2023). Check the package insert in your country.

Why does the mutation need to be tested?

Because tumors with PDGFRA D842V or without a KIT or PDGFRA mutation do not respond to imatinib, and the greatest benefit appears in exon 11 of KIT (Joensuu et al., 2023).

Does an exon 9 mutation call for 800 mg?

In the adjuvant setting, a retrospective European study showed no advantage of 800 mg over 400 mg (Vincenzi et al., 2022).

What counts as rupture?

Fracture or spillage, bloody ascites, perforation in the tumor, infiltration of an adjacent organ, removal in fragments and incisional biopsy, according to the Oslo criteria (Nishida et al., 2019).

Final checklist

• I confirmed complete resection and the diagnosis of GIST.
• I recorded size, mitoses, location and rupture.
• I classified the risk using a recognized system.
• I requested KIT and PDGFRA sequencing.
• I ruled out PDGFRA D842V and GIST without mutation before indicating imatinib.
• I explained the 3-year duration and the expected effects.
• I reviewed drug interactions.
• I planned closer follow-up after stopping treatment.

Want to practice reasoning with progressive clues? Play the case of the day.

References

1. Iwatsuki M, Harada K, Iwagami S, et al. Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors. Ann Gastroenterol Surg. 2019. PMID 30697609.
2. Joensuu H, Eriksson M, Hall KS, et al. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 2014. PMID 24737415.
3. Joensuu H, Reichardt A, Eriksson M, et al. Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial. Br J Cancer. 2024. PMID 38862742.
4. Joensuu H, Wardelmann E, Eriksson M, et al. KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial. Clin Cancer Res. 2023. PMID 37014660.
5. Joensuu H. KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib. Cancers (Basel). 2023. PMID 37568695.
6. Judson I, Jones RL, Wong NACS, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines. Br J Cancer. 2025. PMID 38840030.
7. Mohammad H, Rose HK, Rossen PB, et al. Adjuvant Imatinib for Patients Resected for GIST: A Quality Assurance Study. Cancer Med. 2026. PMID 42120808.
8. Nishida T, Hølmebakk T, Raut CP, et al. Defining Tumor Rupture in Gastrointestinal Stromal Tumor. Ann Surg Oncol. 2019. PMID 30868512.
9. Serrano C, Martín-Broto J, Asencio-Pascual JM, et al. 2023 GEIS Guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol. 2023. PMID 37655207.
10. Vincenzi B, Napolitano A, Fiocco M, et al. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clin Cancer Res. 2022. PMID 34615721.
11. Yoo C, Ryu MH, Jo J, et al. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors. Cancer Res Treat. 2016. PMID 26130666.
12. Zhang H, Liu Q. Prognostic Indicators for Gastrointestinal Stromal Tumors: A Review. Transl Oncol. 2020. PMID 32619820.